Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
HPB · 2024
DOI: 10.1016/j.hpb.2024.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2024. Verfasst von Benjamin J Van Treeck und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy and has a poor prognosis. Surgical resection is the standard of care for patients with resectable disease, representing 30-40% of cases. Increasingly, neoadjuvant systemic therapy is being utilized in patients due to high-risk anatomic or biologic considerations. However, data on the clinical effect of this approach are limited. We performed a cohort study to evaluate the effect of neoadjuvant therapy in patients with oncologically high-risk iCCA. METHODS: iCCA patients (n = 181) between the years 2014-2020 were reviewed for clinical, histopathologic, treatment, and outcome-related data. Tumor regression grade was scored per CAP criteria for gastrointestinal carcinomas. RESULTS: 47 iCCA patients received neoadjuvant therapy and 72 did not. Neoadjuvant treatment led to objective response and tumor regression by CAP score. After adjustment for age, clinical stage, and tumor size, the outcomes of patients who had neoadjuvant therapy followed by surgery were not significantly different from those patients who had surgery first. DISCUSSION: In conclusion, neoadjuvant therapy in iCCA facilitated surgical care. The progression-free and overall survival for surgical patients with and without neoadjuvant therapy were not significantly different suggesting this approach needs further exploration as an effective treatment paradigm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
- Mayo Clinic, Department of Surgery, Department of Biochemistry and Molecular Biology, Rochester, MN, USA.
- Cleveland Clinic, Department of Pathology, Cleveland, OH, USA.
- Mayo Clinic, Department of Quantitative Health Sciences, Rochester, MN, USA.
- Mayo Clinic, Division of Gastroenterology and Hepatology, Department of Immunology, Rochester, MN, USA.
- Mayo Clinic, Department of Oncology, Rochester, MN, USA.
Förderung
- NIMHD NIH HHS
Zitieren
APA
Van Treeck, B. J., Olave, M. C., Watkins, R. D., Lu, H., Moreira, R. K., Mounajjed, T., Johnson, M. J., Smith, C. Y., Ilyas, S. I., Tran, N. H., Jenkins, S. M., Reed, K. A., Smoot, R., Mahipal, A., Allende, D., & Graham, R. P. (2024). Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB. https://doi.org/10.1016/j.hpb.2024.04.003
Vancouver
Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, et al. Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB. 2024. doi:10.1016/j.hpb.2024.04.003
BibTeX
@article{VanTreeck2024,
author = {Van Treeck, Benjamin J and Olave, Maria C and Watkins, Ryan D and Lu, Haiyan and Moreira, Roger K and Mounajjed, Taofic and Johnson, Michael J and Smith, Carin Y and Ilyas, Sumera I and Tran, Nguyen H and Jenkins, Sarah M and Reed, Katelyn A and Smoot, Rory and Mahipal, Amit and Allende, Daniela and Graham, Rondell P},
title = {Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma},
journal = {HPB},
year = {2024},
doi = {10.1016/j.hpb.2024.04.003}
}
EUVIMED